{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002826","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.650904+00:00","generated_at":"2026-06-02T01:12:32.042252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025","bullets":["Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.","Quarter-end cash $5.8M; closed $5.8M PIPE at 25% premium with new investor.","Phase 2 trial of agenT-797 in gastroesophageal cancers actively enrolling; initial results expected H2 2024.","MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models (AACR data).","Upcoming ATS presentation (May 21) on agenT-797 in severe respiratory distress in a renal transplant patient."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002826","json":"https://secwatch.observer/filing/0001171843-24-002826.json","markdown":"https://secwatch.observer/filing/0001171843-24-002826.md","text":"https://secwatch.observer/filing/0001171843-24-002826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/f8k_051424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:12:32.042252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5542d84f80ff8087bda226bc3104e8f056038b7c","claim":"MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.","evidence_excerpt":"Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the first quarter 2024"},{"label":"Net income","value":"$3.8 million, or $0.11 per share"},{"label":"EPS","value":"$0.11 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}